Scientific Evidence


Platform Life Sciences News

Stay updated on the latest news and updates.


Ivermectin for COVID-19: Final Nail in the Coffin

Welcome to Impact Factor, your weekly dose of commentary on a new medical study. I’m Dr F. Perry Wilson of the Yale School of Medicine. It began in a petri dish. Ivermectin, a widely available, cheap, and well-tolerated drug on the WHO’s list of essential medicines for its critical role in treating river blindness, was shown to dramatically reduce the proliferation of SARS-CoV-2 virus in cell culture.

Cheap existing antidepressant likely weapon against Covid-19

Dr. Ed Mills finds fluvoxamine may be game-changer and cut admissions by 30%. A low-cost antidepressant has been shown to significantly reduce the rates of serious illness caused by Covid-19, in a study by an Irish scientist, funded by entrepreneur Patrick Collison.

Demand Surges for Deworming Drug for Covid, Despite Scant Evidence It Works

Prescriptions for ivermectin have jumped to more than 88,000 per week, some pharmacists are reporting shortages and people are overdosing on forms of the drug meant for horses.

How a cheap antidepressant emerged as a promising Covid-19 treatment

Most Covid-19 drug treatments that have been included in trials haven’t panned out. A large new study suggests fluvoxamine might be different. Since Covid-19 patients started showing up at clinics and hospitals a year and a half ago, doctors and researchers have been hard at work trying to figure out how to treat them.

Column: With fluvoxamine, doctors find an old drug that may actually work against COVID-19

The quest for COVID-19 remedies has led patients and doctors into a few dead ends among old established drugs, such as hydroxychloroquine and Ivermectin. But there’s promising news that another generic medicine has shown the ability to moderate the course of the disease.


Shaping the future of clinical trials


Check out our published works